Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365559 | 0.81 | ALDH1A1 (0.94) | KDM4EALDH1A1CACNA1HMEN1KMT2A | |
| SCHEMBL4222713 | 0.79 | ALDH1A1 (0.72) | KDM4EALDH1A1CACNA1HMEN1KMT2A | |
| SCHEMBL26498849 | 0.78 | CACNA1H (1.00) | KDM4EALDH1A1CACNA1HMEN1KMT2A | |
| SCHEMBL4218180 | 0.78 | ALDH1A1 (0.76) | KDM4EALDH1A1CACNA1HPSMB5 | |
| SCHEMBL4218220 | 0.78 | ALDH1A1 (0.67) | KDM4EALDH1A1CACNA1HMEN1KMT2A | |
| SCHEMBL4223025 | 0.77 | ALDH1A1 (0.68) | KDM4EALDH1A1CACNA1HPSMB5EPHX1 | |
| SCHEMBL26464310 | 0.75 | CACNA1H (0.92) | KDM4EALDH1A1CACNA1HKMT2APSMB5 | |
| SCHEMBL4216881 | 0.75 | ALDH1A1 (0.70) | KDM4EALDH1A1CACNA1HEPHX1EPHX2 | |
| SCHEMBL4222774 | 0.75 | KDM4E (0.65) | KDM4EALDH1A1CACNA1HEPHX1EPHX2 | |
| SCHEMBL4215304 | 0.74 | EPHX2 (0.65) | KDM4EALDH1A1CACNA1HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076510-A2 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, IN DIFFERENT CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND FORMULATIONS THEREOF, FOR THE TREATMENT OF THROMBOSIS AND TROMBOSIS RELATED CONDITIONS | Portola Pharmaceuticals, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008137809-A2 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL] -5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, IN DIFFERENT CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1812407-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | Pfizer, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006048750-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | HSD11B1, HSD11B2, HSD17B11 | KDM4E 2439/4885ALDH1A1 50/4885CACNA1H 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.